目的 观察聚乙二醇干扰索α-2a抗病毒治疗对HBeAg阳性慢性乙型肝炎患者记忆性CD8+T淋巴细胞CD127分子表达的影响.方法 30例HBeAg阳性慢性乙型肝炎患者接受聚乙二醇干扰素α-2a治疗,每周1次,共48周.根据CD45RA、CD27分子表达来判定记忆性CD8+T淋巴细胞,以流式细胞术检测CD127在CD8+T淋巴细胞上的表达.组间均数比较采用Mann-Whitney检验.结果 HBeAg阳性慢性乙型肝炎患者在CD45RA-CD27+记忆性CD8+T淋巴细胞上CD127的表达较健康对照组明显降低(Z=2.889,P＜0.05),其表达水平与血清HBV DNA水平和HBeAg呈负相关.聚乙二醇干扰素α-2a抗病毒治疗应答较佳者随着HBV DNA和HBeAg水平的下降,记忆性CD8+T淋巴细胞表面CD127分子的表达在治疗24、48和72周都明显增加,而应答欠佳者则无明显变化(Z24周=1.954,Z48周=2.789,Z72周=2.989;均P＜0.05).结论 慢性乙型肝炎患者通过有效的抗病毒治疗,CD8+T淋巴细胞表达CD127增加,CD127在记忆性CD8+T淋巴细胞上的表达水平可作为判定抗病毒治疗有效的重要标志.%Objective To analyze CD127 expression on the memory CD8+ lymphocytes from hepatitis B e antigen (HBeAg) positive chronic hepatitis B (CHB) patients treated with peginterferon α-2a (Pegasys). Methods Thirty HBeAg positive CHB patients were treated with peginterferon α-2a 180 μg once a week for 48 weeks and followed up for 24 weeks. The memory CD8+ lymphocytes were characterized by expressing CD45RA and CD27 markers. CD127 expression on cell surface was measured by four-colour flow cytometry. The difference of mean values between groups was evaluated by Mann-Whitney test. Results The CD127 expression on CD8+ T lymphocytes was significantly lower in HBeAg positive CHB patients compared to healthy controls (Z=2.889, P＜0.05), which was negatively correlated with serum hepatitis B virus (HBV) DNA level and HBeAg titers. The CD127 expression increased along with the decrease of HBV DNA and HBeAg after 24-week, 48-week and 72-week treatment in patients showing good response to peginterferon α-2a, while CD127 expression didn't change markedly in non responders (Z24w = 1.954, Z48w = 2.789, Z72w = 2. 989; all P＜0. 05). Conclusion CD127 expression on memory CD8+ lymphocytes increases along with effective anti-HBV treatment in CHB patients, which can be used as a marker for evaluating the effectiveness of anti-viral treatment.
展开▼
